Daiwa Securities Group Inc. Trevi Therapeutics, Inc. Transaction History
Daiwa Securities Group Inc.
- $27.1 Billion
- Q2 2025
A detailed history of Daiwa Securities Group Inc. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 305 shares of TRVI stock, worth $3,046. This represents 0.0% of its overall portfolio holdings.
Number of Shares
305
Previous 305
-0.0%
Holding current value
$3,046
Previous $2,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding TRVI
# of Institutions
165Shares Held
110MCall Options Held
1.08MPut Options Held
425K-
Nea Management Company, LLC Timonium, MD13.2MShares$132 Million6.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$102 Million2.96% of portfolio
-
Rubric Capital Management LP New York, NY8.53MShares$85.2 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.32MShares$53.1 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.49MShares$44.8 Million5.2% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $583M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...